Search for a trial

Open-Label Extension Study of EFC12492, R727-CL-1112, EFC12732 and LTS11717 Studies to Assess the Long-Term Safety and Efficacy of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia

Primary objective* To assess the long-term safety of alirocumab when added to currently available lipid-modifying drug therapy in patients with heterozygous familial hypercholesterolemia (heFH) who have completed one of the following studies:…

Long-term treatment for cancer patients with deep vein thrombosis or pulmonary embolism - a randomized open label study

The primary efficacy objective is to evaluate whether LMWH is superior to VKAs in the long-term treatment of symptomatic VTE in cancer patients who completed 6 to 12 months of anticoagulant treatment. Two aspects are important: the efficacy with…

ABSORB BTK TRIAL
A prospective single arm registry of the Absorb Everolimus-eluting bioresorbable vascular scaffold in below the knee atherosclerotic arterial lesions

The aim of this study is to evaluate the efficacy, and feasibility of the Absorb drug-eluting bioresorbable vascular scaffold in infrapopliteal hemodynamically significant arterial stenoses and occlusions.The primary objective is in-stent restenosis…

Effect of Olmesartan Medoxomil on arterial stiffness and thickness in subjects with metabolic syndrome.

to investigate in a descriptive way the dose-dependent effect of Olmesartan Medoxomil 20mg, 40mg en 80mg on arterial stiffness.

A 54-week, open-label, multicenter study to assess the long-term safety and tolerability of the combination of aliskiren 300 mg / valsartan 320 mg in patients with essential hypertension.

The Primary objective is to assess the long-term (6 month and 12 month) safety of the combination of aliskiren 300 mg/ valsartan 320 mg in patients with essential hypertension (msDBP > 90 mmHg and < 110 mmHg.

A Phase III case series clinical study of the reversal of the anticoagulant effects of dabigatran by intravenous administration of 5.0g idarucizumab (BI 655075) in patients treated wtih dabigatran etexilate who have uncontrolled bleeding or require emergency surgery or procedures.

to investigate the safety and efficacy of idarucizumab in reversing the anticoagulation effect of dabigatran, in patients who have uncontrolled bleeding or require emergency surgery or invasive procedures.

An Open-Label Extension Study of UT-15C in Subjects with Pulmonary Arterial Hypertension - A Long-Term Follow-Up to Protocol TDE-PH-310

To provide UT-15C for eligible subjects who participated in study protocol TDE-PH-310

EffecTs of Amlodipine and other Blood PREssure Lowering Agents on Microvascular FuncTion in Small Vessel Diseases

Primary objective:To test the hypothesis that the calcium channel blocker amlodipine has a superior beneficial effect on cerebrovascular reactivity in patients with symptomatic SVDs when compared to either the Angiotensin II type 1 (AT1) receptor…

An extended Access Program to Assess Long-Term Safety of Bardoxolone Methyl in Patients with Pulmonary Hypertension

To provide continuing open-label treatment with bardoxolone methyl as part of this extended access program while collecting ongoing safety and tolerability data of bardoxolone methyl.

Plaque at risk (ParisK): Molecular imaging of plaque vulnerability using 18F-choline PET-MRI in patients with carotid artery atherosclerosis

Primary: -The correlation between 18F-choline uptake in the atherosclerotic plaques on PET-MRI and plaque inflammation on histology, including the content of CD68-positive activated monocytes/macrophages.Secondary: -The correlation between the…